$XLRN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ACCELERON PHARMA INC. Get notifications about new insider transactions in ACCELERON PHARMA INC for free.
Page: < prev 1 2 3 4 5 6 7 ... 11 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Grant | A | 0.00 | 3,850 | 0 | 93,997 | 90.1 K to 94 K (+4.27 %) |
Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | SVP, Chief Commerci ... | Option Exercise | A | 41.64 | 25,500 | 1,061,820 | 25,500 | |
Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | SVP, Chief Commerci ... | Grant | A | 0.00 | 4,050 | 0 | 10,050 | 6 K to 10.1 K (+67.50 %) |
Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, CBO and Secret ... | Option Exercise | A | 41.64 | 28,500 | 1,186,740 | 28,500 | |
Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, CBO and Secret ... | Grant | A | 0.00 | 4,800 | 0 | 57,456 | 52.7 K to 57.5 K (+9.12 %) |
Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | Zeldin Robert K | EVP & Chief Medical ... | Option Exercise | A | 41.64 | 13,000 | 541,320 | 13,000 | |
Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | Zeldin Robert K | EVP & Chief Medical ... | Grant | A | 0.00 | 2,200 | 0 | 19,103 | 16.9 K to 19.1 K (+13.02 %) |
Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | A | 41.64 | 28,000 | 1,165,920 | 28,000 | |
Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Grant | A | 0.00 | 4,700 | 0 | 42,927 | 38.2 K to 42.9 K (+12.29 %) |
Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Option Exercise | A | 41.64 | 106,400 | 4,430,496 | 106,400 | |
Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Grant | A | 0.00 | 17,700 | 0 | 83,968 | 66.3 K to 84 K (+26.71 %) |
Jan 22 2019 | XLRN | ACCELERON PHARMA I ... | CELGENE CORP /DE/ | Buy | P | 43.00 | 706,206 | 30,366,858 | 6,824,685 | 6.1 M to 6.8 M (+11.54 %) | |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 43.94 | 374 | 16,434 | 90,147 | 90.5 K to 90.1 K (-0.41 %) |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 43.20 | 3,051 | 131,803 | 90,521 | 93.6 K to 90.5 K (-3.26 %) |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 42.45 | 2,363 | 100,309 | 93,572 | 95.9 K to 93.6 K (-2.46 %) |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, CBO and Secret ... | Sell | S | 43.92 | 475 | 20,862 | 52,656 | 53.1 K to 52.7 K (-0.89 %) |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, CBO and Secret ... | Sell | S | 43.10 | 2,558 | 110,250 | 53,131 | 55.7 K to 53.1 K (-4.59 %) |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, CBO and Secret ... | Sell | S | 42.31 | 1,300 | 55,003 | 55,689 | 57 K to 55.7 K (-2.28 %) |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, CBO and Secret ... | Sell | S | 43.26 | 300 | 12,978 | 56,989 | 57.3 K to 57 K (-0.52 %) |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, CBO and Secret ... | Sell | S | 42.32 | 1,309 | 55,397 | 57,289 | 58.6 K to 57.3 K (-2.23 %) |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 44.06 | 97 | 4,274 | 38,227 | 38.3 K to 38.2 K (-0.25 %) |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 43.33 | 1,717 | 74,398 | 38,324 | 40 K to 38.3 K (-4.29 %) |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 42.56 | 2,186 | 93,036 | 40,041 | 42.2 K to 40 K (-5.18 %) |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 43.20 | 300 | 12,960 | 42,227 | 42.5 K to 42.2 K (-0.71 %) |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 42.37 | 1,412 | 59,826 | 42,527 | 43.9 K to 42.5 K (-3.21 %) |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Sell | S | 40.85 | 27 | 1,103 | 66,268 | 66.3 K to 66.3 K (-0.04 %) |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Sell | S | 43.45 | 1,930 | 83,859 | 66,295 | 68.2 K to 66.3 K (-2.83 %) |
Dec 06 2018 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Sell | S | 54.33 | 700 | 38,031 | 68,225 | 68.9 K to 68.2 K (-1.02 %) |
Dec 06 2018 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Sell | S | 53.65 | 5,607 | 300,816 | 68,925 | 74.5 K to 68.9 K (-7.52 %) |
Dec 06 2018 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Sell | S | 52.72 | 3,862 | 203,605 | 74,532 | 78.4 K to 74.5 K (-4.93 %) |
Dec 06 2018 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Sell | S | 51.54 | 2,506 | 129,159 | 78,394 | 80.9 K to 78.4 K (-3.10 %) |
Aug 31 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 27.97 | 12,500 | 349,625 | 18,300 | |
Aug 31 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 54.00 | 12,500 | 675,000 | 43,939 | 56.4 K to 43.9 K (-22.15 %) |
Aug 31 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 27.97 | 12,500 | 349,625 | 56,439 | 43.9 K to 56.4 K (+28.45 %) |
Jul 05 2018 | XLRN | ACCELERON PHARMA I ... | Zeldin Robert K | EVP & Chief Medical ... | Option Exercise | A | 47.33 | 85,511 | 4,047,236 | 85,511 | |
Jul 05 2018 | XLRN | ACCELERON PHARMA I ... | Zeldin Robert K | EVP & Chief Medical ... | Grant | A | 0.00 | 16,903 | 0 | 16,903 | 0 to 16.9 K |
Jul 03 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 24.11 | 25,000 | 602,750 | 4,000 | |
Jul 03 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 49.00 | 12,500 | 612,500 | 43,939 | 56.4 K to 43.9 K (-22.15 %) |
Jul 03 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 47.00 | 12,500 | 587,500 | 56,439 | 68.9 K to 56.4 K (-18.13 %) |
Jul 03 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 24.11 | 25,000 | 602,750 | 68,939 | 43.9 K to 68.9 K (+56.90 %) |
Apr 04 2018 | XLRN | ACCELERON PHARMA I ... | Rovaldi Christopher | SVP, Program Mgmt a ... | Sell | S | 39.02 | 600 | 23,412 | 25,858 | 26.5 K to 25.9 K (-2.27 %) |
Apr 04 2018 | XLRN | ACCELERON PHARMA I ... | Rovaldi Christopher | SVP, Program Mgmt a ... | Sell | S | 38.27 | 2,900 | 110,983 | 26,458 | 29.4 K to 26.5 K (-9.88 %) |
Apr 04 2018 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 39.16 | 100 | 3,916 | 95,935 | 96 K to 95.9 K (-0.10 %) |
Apr 04 2018 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 38.34 | 1,103 | 42,289 | 96,035 | 97.1 K to 96 K (-1.14 %) |
Apr 04 2018 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Sell | S | 39.16 | 100 | 3,916 | 56,598 | 56.7 K to 56.6 K (-0.18 %) |
Apr 04 2018 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Sell | S | 38.33 | 1,104 | 42,316 | 56,698 | 57.8 K to 56.7 K (-1.91 %) |
Apr 04 2018 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 39.04 | 900 | 35,136 | 68,767 | 69.7 K to 68.8 K (-1.29 %) |
Apr 04 2018 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 38.28 | 3,700 | 141,636 | 69,667 | 73.4 K to 69.7 K (-5.04 %) |
Apr 04 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 39.00 | 800 | 31,200 | 43,939 | 44.7 K to 43.9 K (-1.79 %) |
Apr 04 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 38.31 | 3,200 | 122,592 | 44,739 | 47.9 K to 44.7 K (-6.68 %) |
Mar 23 2018 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Option Exercise | M | 5.08 | 18,750 | 95,250 | 0 | |
Mar 23 2018 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Option Exercise | M | 5.08 | 18,750 | 95,250 | 0 | |
Mar 23 2018 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Buy | M | 5.08 | 18,750 | 95,250 | 135,481 | 116.7 K to 135.5 K (+16.06 %) |
Mar 23 2018 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Buy | M | 5.08 | 18,750 | 95,250 | 135,481 | 116.7 K to 135.5 K (+16.06 %) |
Mar 08 2018 | XLRN | ACCELERON PHARMA I ... | POPS RICHARD F | Director | Option Exercise | M | 5.08 | 37,500 | 190,500 | 0 | |
Mar 08 2018 | XLRN | ACCELERON PHARMA I ... | POPS RICHARD F | Director | Sell | S | 42.32 | 2,902 | 122,813 | 31,250 | 34.2 K to 31.3 K (-8.50 %) |
Mar 08 2018 | XLRN | ACCELERON PHARMA I ... | POPS RICHARD F | Director | Sell | S | 41.34 | 34,598 | 1,430,281 | 34,152 | 68.8 K to 34.2 K (-50.32 %) |
Mar 08 2018 | XLRN | ACCELERON PHARMA I ... | POPS RICHARD F | Director | Buy | M | 5.08 | 37,500 | 190,500 | 68,750 | 31.3 K to 68.8 K (+120.00 %) |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Option Exercise | A | 40.61 | 7,500 | 304,575 | 7,500 | |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Grant | A | 0.00 | 1,250 | 0 | 6,500 | 5.3 K to 6.5 K (+23.81 %) |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | A | 40.61 | 1,875 | 76,144 | 1,875 | |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Grant | A | 0.00 | 312 | 0 | 312 | 0 to 312 |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | POPS RICHARD F | Director | Option Exercise | A | 40.61 | 7,500 | 304,575 | 7,500 | |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | POPS RICHARD F | Director | Grant | A | 0.00 | 1,250 | 0 | 31,250 | 30 K to 31.3 K (+4.17 %) |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Option Exercise | A | 40.61 | 7,500 | 304,575 | 7,500 | |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Grant | A | 0.00 | 1,250 | 0 | 1,795 | 545 to 1.8 K (+229.36 %) |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Option Exercise | A | 40.61 | 7,500 | 304,575 | 7,500 | |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Grant | A | 0.00 | 1,250 | 0 | 2,500 | 1.3 K to 2.5 K (+100.00 %) |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Option Exercise | A | 40.61 | 7,500 | 304,575 | 7,500 | |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Grant | A | 0.00 | 1,250 | 0 | 2,500 | 1.3 K to 2.5 K (+100.00 %) |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | A | 40.61 | 26,775 | 1,087,333 | 26,775 | |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Grant | A | 0.00 | 4,463 | 0 | 97,138 | 92.7 K to 97.1 K (+4.82 %) |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Rovaldi Christopher | SVP, Program Mgmt a ... | Option Exercise | A | 40.61 | 24,375 | 989,869 | 24,375 | |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Rovaldi Christopher | SVP, Program Mgmt a ... | Grant | A | 0.00 | 4,063 | 0 | 28,764 | 24.7 K to 28.8 K (+16.45 %) |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | SVP, Chief Commerci ... | Option Exercise | A | 40.61 | 50,000 | 2,030,500 | 50,000 | |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Option Exercise | A | 40.61 | 28,950 | 1,175,660 | 28,950 | |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Grant | A | 0.00 | 4,825 | 0 | 57,802 | 53 K to 57.8 K (+9.11 %) |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | A | 40.61 | 30,825 | 1,251,803 | 30,825 | |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Grant | A | 0.00 | 5,138 | 0 | 47,939 | 42.8 K to 47.9 K (+12.00 %) |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Option Exercise | A | 40.61 | 108,800 | 4,418,368 | 108,800 | |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Grant | A | 0.00 | 18,100 | 0 | 80,900 | 62.8 K to 80.9 K (+28.82 %) |
Feb 13 2018 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | SVP, Chief Commerci ... | Grant | A | 0.00 | 6,000 | 0 | 6,000 | 0 to 6 K |
Jan 17 2018 | XLRN | ACCELERON PHARMA I ... | Rovaldi Christopher | SVP, Program Mgmt a ... | Option Exercise | M | 24.11 | 11,000 | 265,210 | 12,000 | |
Jan 17 2018 | XLRN | ACCELERON PHARMA I ... | Rovaldi Christopher | SVP, Program Mgmt a ... | Sell | S | 45.00 | 11,000 | 495,000 | 24,701 | 35.7 K to 24.7 K (-30.81 %) |
Jan 17 2018 | XLRN | ACCELERON PHARMA I ... | Rovaldi Christopher | SVP, Program Mgmt a ... | Buy | M | 24.11 | 11,000 | 265,210 | 35,701 | 24.7 K to 35.7 K (+44.53 %) |
Jan 04 2018 | XLRN | ACCELERON PHARMA I ... | Rovaldi Christopher | SVP, Program Mgmt a ... | Sell | S | 42.45 | 833 | 35,361 | 24,701 | 25.5 K to 24.7 K (-3.26 %) |
Jan 04 2018 | XLRN | ACCELERON PHARMA I ... | Rovaldi Christopher | SVP, Program Mgmt a ... | Sell | S | 42.41 | 1,433 | 60,774 | 25,534 | 27 K to 25.5 K (-5.31 %) |
Jan 04 2018 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 42.41 | 4,300 | 182,363 | 92,675 | 97 K to 92.7 K (-4.43 %) |
Jan 04 2018 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Sell | S | 42.42 | 4,333 | 183,806 | 52,977 | 57.3 K to 53 K (-7.56 %) |
Jan 04 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 5.28 | 6,250 | 33,000 | 0 | |
Jan 04 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 6,251 | 24,254 | 0 | |
Jan 04 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 43.84 | 200 | 8,768 | 42,801 | 43 K to 42.8 K (-0.47 %) |
Jan 04 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 43.00 | 14,800 | 636,400 | 43,001 | 57.8 K to 43 K (-25.61 %) |
Jan 04 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 5.28 | 6,250 | 33,000 | 57,801 | 51.6 K to 57.8 K (+12.12 %) |
Jan 04 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 6,251 | 24,254 | 51,551 | 45.3 K to 51.6 K (+13.80 %) |
Jan 04 2018 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 42.42 | 4,000 | 169,680 | 45,300 | 49.3 K to 45.3 K (-8.11 %) |
Jan 04 2018 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 43.33 | 2,033 | 88,090 | 73,367 | 75.4 K to 73.4 K (-2.70 %) |
Jan 04 2018 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 42.40 | 2,300 | 97,520 | 75,400 | 77.7 K to 75.4 K (-2.96 %) |
Jan 04 2018 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 40.86 | 300 | 12,258 | 77,700 | 78 K to 77.7 K (-0.38 %) |
Dec 18 2017 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Sell | S | 35.73 | 105,122 | 3,756,009 | 0 | 105.1 K to 0 (-100.00 %) |
Nov 15 2017 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | A | 35.34 | 20,000 | 706,800 | 20,000 | |
Sep 29 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 5.28 | 6,761 | 35,698 | 0 | |
Sep 29 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 5.28 | 6,761 | 35,698 | 96,975 | 90.2 K to 97 K (+7.49 %) |
Sep 25 2017 | XLRN | ACCELERON PHARMA I ... | CELGENE CORP /DE/ | 10% Owner | Buy | P | 37.00 | 745,592 | 27,586,904 | 6,118,479 | 5.4 M to 6.1 M (+13.88 %) |
Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Rovaldi Christopher | SVP, Program Mgmt a ... | Sell | S | 39.96 | 100 | 3,996 | 26,967 | 27.1 K to 27 K (-0.37 %) |
Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Rovaldi Christopher | SVP, Program Mgmt a ... | Sell | S | 39.30 | 1,165 | 45,785 | 27,067 | 28.2 K to 27.1 K (-4.13 %) |
Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Rovaldi Christopher | SVP, Program Mgmt a ... | Sell | S | 38.32 | 12,735 | 488,005 | 28,232 | 41 K to 28.2 K (-31.09 %) |
Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 38.12 | 8 | 305 | 90,214 | 90.2 K to 90.2 K (-0.01 %) |
Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 39.39 | 500 | 19,695 | 90,222 | 90.7 K to 90.2 K (-0.55 %) |
Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 38.31 | 4,605 | 176,418 | 90,722 | 95.3 K to 90.7 K (-4.83 %) |
Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Sell | S | 38.03 | 8 | 304 | 57,310 | 57.3 K to 57.3 K (-0.01 %) |
Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Sell | S | 39.37 | 600 | 23,622 | 57,318 | 57.9 K to 57.3 K (-1.04 %) |
Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Sell | S | 38.29 | 4,505 | 172,496 | 57,918 | 62.4 K to 57.9 K (-7.22 %) |
Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 39.91 | 150 | 5,987 | 78,000 | 78.2 K to 78 K (-0.19 %) |
Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 39.24 | 1,600 | 62,784 | 78,150 | 79.8 K to 78.2 K (-2.01 %) |
Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 38.32 | 16,650 | 638,028 | 79,750 | 96.4 K to 79.8 K (-17.27 %) |
Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 39.85 | 210 | 8,369 | 49,300 | 49.5 K to 49.3 K (-0.42 %) |
Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 39.17 | 1,300 | 50,921 | 49,510 | 50.8 K to 49.5 K (-2.56 %) |
Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 38.32 | 14,490 | 555,257 | 50,810 | 65.3 K to 50.8 K (-22.19 %) |
Aug 09 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 24.11 | 13,065 | 314,997 | 3,624 | |
Aug 09 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 35.41 | 13,065 | 462,632 | 95,327 | 108.4 K to 95.3 K (-12.05 %) |
Aug 09 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 24.11 | 13,065 | 314,997 | 108,392 | 95.3 K to 108.4 K (+13.71 %) |
Jul 07 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 7.12 | 937 | 6,671 | 0 | |
Jul 07 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 32.00 | 937 | 29,984 | 95,327 | 96.3 K to 95.3 K (-0.97 %) |
Jul 07 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 7.12 | 937 | 6,671 | 96,264 | 95.3 K to 96.3 K (+0.98 %) |
Jul 07 2017 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 7.12 | 18,750 | 133,500 | 0 | |
Jul 07 2017 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 5.28 | 3,150 | 16,632 | 6,250 | |
Jul 07 2017 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 32.00 | 34,400 | 1,100,800 | 65,300 | 99.7 K to 65.3 K (-34.50 %) |
Jul 07 2017 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 7.12 | 18,750 | 133,500 | 99,700 | 81 K to 99.7 K (+23.16 %) |
Jul 07 2017 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 5.28 | 3,150 | 16,632 | 80,950 | 77.8 K to 81 K (+4.05 %) |
Jul 07 2017 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 7.12 | 8,000 | 56,960 | 0 | |
Jul 07 2017 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 32.00 | 16,000 | 512,000 | 96,400 | 112.4 K to 96.4 K (-14.23 %) |
Jul 07 2017 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 7.12 | 8,000 | 56,960 | 112,400 | 104.4 K to 112.4 K (+7.66 %) |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Option Exercise | A | 30.17 | 7,500 | 226,275 | 7,500 | |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Grant | A | 0.00 | 1,250 | 0 | 5,250 | 4 K to 5.3 K (+31.25 %) |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | POPS RICHARD F | Director | Option Exercise | A | 30.17 | 7,500 | 226,275 | 7,500 | |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | POPS RICHARD F | Director | Grant | A | 0.00 | 1,250 | 0 | 30,000 | 28.8 K to 30 K (+4.35 %) |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Option Exercise | A | 30.17 | 7,500 | 226,275 | 7,500 | |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Grant | A | 0.00 | 1,250 | 0 | 1,250 | 0 to 1.3 K |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Option Exercise | A | 30.17 | 3,272 | 98,716 | 3,272 | |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Grant | A | 0.00 | 545 | 0 | 545 | 0 to 545 |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Option Exercise | A | 30.17 | 7,500 | 226,275 | 7,500 | |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Grant | A | 0.00 | 1,250 | 0 | 115,481 | 114.2 K to 115.5 K (+1.09 %) |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Kearney Terrence C | Director | Option Exercise | A | 30.17 | 7,500 | 226,275 | 7,500 | |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Kearney Terrence C | Director | Grant | A | 0.00 | 1,250 | 0 | 1,250 | 0 to 1.3 K |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Option Exercise | A | 30.17 | 7,500 | 226,275 | 7,500 | |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Grant | A | 0.00 | 1,250 | 0 | 1,250 | 0 to 1.3 K |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Option Exercise | A | 30.17 | 7,500 | 226,275 | 7,500 | |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Grant | A | 0.00 | 1,250 | 0 | 1,250 | 0 to 1.3 K |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | A | 30.17 | 41,300 | 1,246,021 | 41,300 |